Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer

Lung cancer is a leading cause of cancer death, where the amplification of oncogenes contributes to tumorigenesis. Genomic profiling of 128 lung cancer cell lines and tumors revealed frequent focal DNA amplification at cytoband 14q13.3, a locus not amplified in other tumor types. The smallest region...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 27; no. 25; pp. 3635 - 3640
Main Authors Kwei, K A, Kim, Y H, Girard, L, Kao, J, Pacyna-Gengelbach, M, Salari, K, Lee, J, Choi, Y-L, Sato, M, Wang, P, Hernandez-Boussard, T, Gazdar, A F, Petersen, I, Minna, J D, Pollack, J R
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 05.06.2008
Nature Publishing
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Lung cancer is a leading cause of cancer death, where the amplification of oncogenes contributes to tumorigenesis. Genomic profiling of 128 lung cancer cell lines and tumors revealed frequent focal DNA amplification at cytoband 14q13.3, a locus not amplified in other tumor types. The smallest region of recurrent amplification spanned the homeobox transcription factor TITF1 (thyroid transcription factor 1; also called NKX2-1 ), previously linked to normal lung development and function. When amplified, TITF1 exhibited increased expression at both the RNA and protein levels. Small interfering RNA (siRNA)-mediated knockdown of TITF1 in lung cancer cell lines with amplification led to reduced cell proliferation, manifested by both decreased cell-cycle progression and increased apoptosis. Our findings indicate that TITF1 amplification and overexpression contribute to lung cancer cell proliferation rates and survival and implicate TITF1 as a lineage-specific oncogene in lung cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0950-9232
1476-5594
DOI:10.1038/sj.onc.1211012